Characteristics, Treatment Patterns, and Glycemic Control of Older Type 2 Diabetes Mellitus Patients in China
Xiao-Ling Cai,Jie Shen,Bin-Qi Ye,Qiang Li,Douglas A. S. Clark,Li-Nong Ji
DOI: https://doi.org/10.1097/cm9.0000000000001674
IF: 6.133
2021-01-01
Chinese Medical Journal
Abstract:To the Editor: The prevalence of type 2 diabetes mellitus (T2DM) in older Chinese adults (≥60 years) is over 20%.[1] In comparison to younger patients, older diabetes patients tend to have lower rate of adequate glycemic control (<7.0% hemoglobin A1c [HbA1c]) and a higher risk of hypoglycemia.[2] Currently, there are limited data on the clinical characteristics and treatment patterns of older T2DM patients in China. We conducted a nationwide cross-sectional study to examine the clinical characteristics, anti-diabetic treatment patterns, and glycemic control in older (≥60 years) Chinese patients. Factors associated with poor glycemic control were identified with multivariate regression analysis. This study was conducted between March 2017 and December 2017 at 18 hospitals across China (Supplementary Appendix I, https://links.lww.com/CM9/A712). T2DM was diagnosed by the 1999 World Health Organization criteria. Patients participating in other clinical studies were excluded. The study protocol was approved by the ethics committees of all participating centers. The study was conducted in accordance with the Declaration of Helsinki. All participants provided written informed consent. The primary outcome was the proportion of patients who attained HbA1c <7%. The secondary outcomes included treatment patterns, proportion of patients with history of hypoglycemia, hypoglycemia leading to therapy change, or macrovascular and microvascular complications. Sample size requirement was estimated based on the following assumptions: (1) 39% HbA1c <7% attainment rate[3]; (2) two-sided 95% confidence interval (CI) not exceeding 5%; (3) 97.5% availability of the HbA1c data. The calculation yielded 1500 subjects. Multivariate logistic regression was conducted to identify factors associated with poor glycemic control, with the results shown as adjusted odds ratio (OR) and 95% CI. The study flowchart is shown in Supplementary Figure 1, https://links.lww.com/CM9/A767. The final analysis included 1520 subjects (67.7 ± 5.9 years of age; 819 women). Baseline characteristics are shown in Supplementary Table 1, https://links.lww.com/CM9/A709. The mean HbA1c was 7.5% ± 1.5%. The mean fasting plasma glucose was 8.27 ± 2.73 mmol/L. The rate of microalbuminuria and macroalbuminuria was 27.6% and 7.1%, respectively. Overall, 43.4% patients achieved HbA1c <7% [Table 1]. The target attainment rate was 31.9% in patients ≥80 years of age vs. 40.5% at 70 to 79 years and 45.4% at 60 to 69 years. The target attainment rate was 48.7% (472/969), 32.1% (135/420), and 38.0% (41/108) among those without albuminuria, micro-albuminuria, and with macro-albuminuria, respectively. Furthermore, 53.7% patients with ≤1 year disease duration achieved the HbA1c target, compared to 38.4% among those with ≥10 years disease duration. In multivariate logistic regression, the following factors were associated with lower probability to attain the HbA1c control target: older age (OR for ≥80 years = 0.60, 95% CI 0.35–1.05, vs. 60–70 years), albuminuria (OR for micro-albuminuria = 0.53, 95% CI 0.41–0.68, vs. normal), and longer disease duration of T2MD (OR for >5 to ≤10 years = 0.68, 95% CI 0.47–0.99; OR for >10 years = 0.57, 95% CI 0.41–0.79, vs. ≤1 year). Table 1 - The target attainment rate of adequate glycemic control (HbA1c <7%), stratified by patient variables, n (%). Variables Patients with HbA1c <7%, n (%) Total 660 (43.4) Stratified by age 60–69 years 466 (45.4) 70–79 years 171 (40.5) ≥80 years 23 (31.9) Stratified by albuminuria level Without albuminuria 472 (48.7) Microalbuminuria 135 (32.1) Macroalbuminuria 41 (38.0) Missing 12 Stratified by duration of diabetes ≤ 1 year 108 (53.7) 1< and ≤5 years 130 (50.0) 5< and ≤10 years 130 (43.5) >10 years 279 (38.4) Missing 13 Stratified by sex Male 310 (44.2) Female 350 (42.7) Stratified by smoking status Never smokers 453 (43.5) Former smokers 123 (45.6) Current smokers 84 (40.6) Stratified by physical activity Yes 566 (44.0) No 94 (40.3) Stratified by BMI <24 kg/m2 247 (44.4) ≥24 and <28 kg/m2 302 (43.0) ≥28 kg/m2 109 (42.4) Missing 2 BMI: Body mass index. Overall, 16.8% patients received oral anti-diabetic drug (OAD) monotherapy, 28.7% received OAD combination therapy, 28.3% received OAD plus insulin, and 15.5% received insulin only [Supplementary Table 2, https://links.lww.com/CM9/A710]. The remaining 10.1% patients received diet and exercise only or no intervention at all. For OAD monotherapy, biguanides (8.6% of total) were the most frequently used agent, followed by α-glucosidase inhibitors (3.9%) and sulfonylureas (2.7%). The top three dual combinations were biguanide plus sulfonylurea (6.4%), biguanide plus α-glucosidase inhibitor (4.7%), and α-glucosidase inhibitor plus sulfonylureas (3.2%). The most common triple OAD therapy was biguanide combined with α-glucosidase inhibitor and sulfonylurea (5.1%). The most commonly used OADs in combination with insulin were biguanides (6.1%), α-glucosidase inhibitors (5.9%), and sulfonylureas (1.1%). Dipeptidyl peptidase (DPP)-4 inhibitors were used in 4.7%; even fewer patients received sodium-glucose cotransporter (SGLT)-2 inhibitors (0.3%) and glucagon-like peptide (GLP)-1 receptor agonists (0.1%). Cardiovascular disease was the most common complication (14.9%), followed by retinopathy (14.4%), neuropathy (13.6%), cerebrovascular disease (11.2%), peripheral vascular disease (8.8%), and diabetic kidney disease (8.6%). The proportion of patients who experienced hypoglycemia was 28.0% (426/1520) in the entire study population, 30.3% (160/528) in patients with albuminuria, and 30.8% (123/399) in patients with albuminuria but normal urine white blood cells (WBCs) [Supplementary Table 3, https://links.lww.com/CM9/A711]. The proportion of patients with hypoglycemia leading to therapy change was 7.2% in the overall study population, 7.2% in patients with albuminuria, and 6.8% in patients with albuminuria but normal urine WBCs. No other safety events were reported. The rate of hypoglycemia was 15.3% for OAD monotherapy vs. 20.9% for OAD combination. Among the patients receiving 2-drug combination, the rate of hypoglycemia was 25.5% for biguanides plus sulfonylureas, 19.7% for biguanides plus α-glucosidase inhibitors, and 12.3% for α-glucosidase inhibitors plus sulfonylureas. The rate of hypoglycemia was 24.4% for 3-drug combination (biguanides, α-glucosidase inhibitors plus sulfonylureas). The rate of hypoglycemia was 51.7% for insulin only and 34.9% for insulin plus OAD. To summarize, only 43.4% patients in the current study attained HbA1c <7%. Consistent with previous studies,[4] poor glycemic control was associated with older age (≥80 years), albuminuria (both micro- and macro-) and longer disease duration (>5 years). Treatment patterns revealed in the current study may warrant some concern. Consistent with major guidelines that recommend biguanides as first-line medication as well as previous studies,[5] biguanides were the most commonly used OAD, either as monotherapy or in combination therapy. However, several drugs that known to be associated with higher risk of hypoglycemia (eg, sulfonylureas, meglitinides, and insulin) were also widely used. In contrast, the use of newer agents with low risk of hypoglycemia (eg, DPP-4 inhibitors) was low in the current study. We speculate that the relatively high rate of hypoglycemia in the current study (28.0%) could be attributed, at least in part, to the use of agents with relatively high risk of hypoglycemia. SGLT-2 inhibitors and GLP-1 receptor agonists could reduce cardiovascular risk, and have been recommended by major guidelines as initial combination or second-line therapy in patients with high risk of cardiovascular diseases. Of note, only 0.3% and 0.1% patients received SGLT-2 inhibitors and GLP-1 receptor agonists, respectively. As an observational study, the sample size of the current study is relatively small. More importantly, all participating hospitals were tertiary or secondary hospitals. Considering the generally lower rate of adherence to guidelines, situation in community and rural hospitals may be considerably different. In summary, more than half of Chinese T2DM patients over 60 years of age failed to attain adequate glycemic control. Poor glycemic control was associated with older age, albuminuria, and longer disease duration. The rate of hypoglycemia was relatively high, and may be related to treatment patterns (high rate of sulfonylureas, meglitinides and insulin, and low rate of DPP-4 inhibitors). GLP-1 receptor agonists and SGLT-2 inhibitors were used rarely. Acknowledgement The authors thank the investigators listed below for their supports in this study: Zhi-Feng Cheng from the Fourth Affiliated Hospital of Harbin Medical University, Xiao-Yan Chen from the First Affiliated Hospital of Guangzhou Medical University, Jian-Hua Ma from Nanjing First Hospital, Wen-Bo Wang from Peking University Shougang Hospital, Chao Liu from Jiangsu Province Hospital of Integration of Chinese and Western Medicine, Nai-Long Yang from the Affiliated Hospital of Qingdao University, Hong-Mei Li from China Meitan General Hospital, Bi-Min Shi from the First Affiliated Hospital of Soochow University, Li-Xin Guo from Beijing Hospital, Li-Jing Jia from Shenzhen People's Hospital, Gui-Xia Wang from the First Bethune Hospital of Jilin University, Hong-Wei Jiang from the First Affiliated Hospital of Henan University of Science and Technology, Qiu Chen from the Affiliated Hospital of Chengdu University of TCM, Yu-Feng Li from Beijing Pinggu Hospital, Shi-Wei Cui from Affiliated Hospital of Nantong University, Chun Wang from West China Hospital Sichuan University, Jian-Ling Du from the First Affiliated Hospital of Dalian Medical University, Chang-Jiang Wang from the First Affiliated Hospital of Anhui Medical University. The authors also thank Xiao-Qin Tong, a Clinical Project Manager of Boehringer Ingelheim (China) Investment Co., Ltd, for her support in this study. Funding This study was sponsored by Boehringer Ingelheim and Eli Lilly. Conflicts of interest Li-Nong Ji has received fees for lecture presentations and consulting from AstraZeneca, Merck, Novartis, Lilly, Roche, Sanofi-Aventis, and Takeda. He has also received grants/research support from AstraZeneca, Bristol-Myers Squibb, Merck, Novartis, and Sanofi-Aventis.